Vitamin B12 Supplement Manufacturer

Starting paths, not ranked SKUs. A vegan cyanocobalamin tablet is still F03 + F06. Sublingual is a format file, not a proof of better absorption.

Send Your BOM if the brief already names INN, mcg, and format.

A vitamin B12 private label manufacturer quote and a raw-cobalamin offer are not the same RFQ. Comparing a methylcobalamin manufacturer path with a cyanocobalamin manufacturer path only works after both INNs, packs, and assay files are named.

If you are comparing two OEM suppliers, ask five questions first.

1. Do they assay finished tablets, capsules, pieces, or millilitres — or only the incoming drum?
2. Can they validate microgram content uniformity (premix, blend, then finished CU)?
3. Is methylcobalamin stability shown on your commercial pack, not a generic bottle?
4. Can one artwork program cover more than one dosage form — tablet, capsule, sublingual, liquid — as separate files?
5. Can they supply destination-market documentation (identity, assay, micro, metals, and the claim file)?

Those five answers usually separate a finished-product manufacturer from a raw-material trader. KS Nutripharma is a vitamin B12 contract manufacturer for OEM and ODM oral SKUs; we quote the finished unit. Supplement contract manufacturing.

A good vitamin B12 OEM manufacturer typically locks finished assay, a stability protocol on the pack you will ship, a pilot before the commercial batch, pack validation (light, moisture, seal), blend sampling, and artwork review against the destination claim file. That list is a screening file — not a ranking of named competitors.

Bring the file below. Missing lines are why two OEM quotations are not comparable.

• Destination market
• Dosage form (tablet, capsule, sublingual, liquid, or a scoped stick/gummy/softgel)
• Cobalamin INN
• Target mcg and potency basis
• Label-claim constraints (structure/function; no deficiency-treatment copy)
• Packaging (bottle vs blister; light and moisture)
• Bottle count (headspace on liquids)
• Shelf-life conversation (data on that SKU — not a catalog month)
• Existing COA or Supplement Facts
• Artwork status

Send Your BOM when those lines are named.

Cobalamin is sourced on the finished-supplement project. F02 and F03 are the commercial SKUs; this table is the purchase-order lock.

Cyanocobalamin is usually the more photostable oral salt, so we often run a lighter overage and pack file. Methylcobalamin more often needs a harder light/moisture file; we treat overage as a pack-specific number confirmed on pilot, not a catalog percentage copied from the raw COA.

Freeze labeled mcg and INN basis before comparing quotes.

Public adult reference intakes sit at low-single-digit mcg per day in nutrition references. Commercial panels often show 500, 1,000, 2,500, or 5,000 mcg. Catalog microgram levels exist in part because intrinsic-factor uptake saturates and a small fraction can still move by passive diffusion. That is serving architecture. It does not make 1,000 mcg the recommended daily intake.

%DV, RDI, and NRV follow the destination label file. One potency basis per SKU.

A development checklist — not a consumer ranking.

Most quote mismatches come from an unlocked file, not from tablet hardness.

Buyer-side holds we see before the first PO.

1. Choosing methylcobalamin only because it sounds premium. The INN is a specification, not a ranking. Cyanocobalamin remains the usual cost-stable tablet file.
2. Using a raw COA as the finished COA. Microgram CU lives on the tablet, capsule, piece, or millilitre you ship.
3. Skipping content uniformity on a 500–1,000 mcg solid.
4. Changing the bottle after stability was run. Count, resin, opacity, liner, and desiccant are part of the assay file.
5. Blending probiotic CFU with B12 without a compatibility study. Water activity usually argues for a dual SKU.

Use the same list on every RFQ. The answers tell you whether the quote is a finished SKU or a raw-material pass-through.

Send Your Brief

Typical commercial framing: daily nutrition, plant-based assortments (reliable food sources of B12 are limited — a market fact), or an energy-adjacent set. Structure/function wording is a destination-market file.

United States: dietary-supplement structure/function rules. European Union: authorized health-claim lists.

For the brand’s warning set — not a self-diagnosis tool.

Possible complaints include gastrointestinal discomfort. Sensitivity or rash belongs on the label when the destination market requires it. Incidence rates are not published for an untested formula.

Public references often discuss oral B12 as having low toxicity and, in some jurisdictions, no established upper intake level. F08 is still a development and artwork choice, not “any mcg is fine.”

Vegan claims, pregnancy as a labeled population, metformin or acid-reducing medicines, and absorption-surgery history go to destination-market counsel. Folate masking stays on the F09 artwork file. Iron and B6 keep their own GI, interaction, and odor files.

Release path we actually run: Incoming identity → premix → blend uniformity → compression or fill → finished assay on the unit → pack → QA release. Out-of-spec results go on hold for investigation until QA closes the deviation.

At 500 mcg or 1,000 mcg, vitamin B12 is typically well below 1% of a 300–800 mg tablet or capsule weight (a 500 mcg charge in a 500 mg tablet is 0.1%). The hard step is micro-dose distribution. Our formulation team normally builds a geometric premix before final blending rather than charging neat vitamin into the production blender. Incoming HPLC on the drum still matters; it does not replace blend-uniformity checks and finished content uniformity.

Premix and blend sampling. The premix is sampled before it enters the production blender. The blend is sampled at multiple locations — typically beginning, middle, and end of discharge — before compression or fill. Finished tablets or capsules follow the content-uniformity plan on the specification. When the RFQ cites USP 905 or Ph. Eur. content uniformity, that is the acceptance file we write to. We do not invent a house CU number that contradicts the destination spec.

Cyanocobalamin lots more often keep a modest overage once the pack is ordinary opaque HDPE. Methylcobalamin lots more often wait until we have pilot results on that bottle (or blister) under light and accelerated conditions, then freeze overage. We do not copy one catalog overage onto both salts.

In-house lab plus SGS/Eurofins when the RFQ requires a third-party report. Quality control. Methylcobalamin and liquid SKUs: Moisture Control & Stability Engineering.

Request a Sample / COA

Pack is part of the assay file. Count and shipping come after light, moisture, and seal.

Why not a clear bottle? Visible light is a methylcobalamin and liquid assay problem. Clear PET is a brand look, not a stability strategy, unless the stability protocol on that SKU says otherwise. Opaque HDPE is the usual tablet/capsule start because it blocks light and travels well. Amber PET (or equivalent) is the usual liquid start because you still need to see fill level and fit a dropper.

HDPE vs PET. HDPE: tablets and capsules, impact, light block, lower cost on opaque counts. PET: liquids and some retail looks; choose amber when the INN or solution is light-sensitive. Clear PET on methylcobalamin is a hold waiting to happen unless foil, carton, and protocol offset it — say so on the RFQ.

Headspace. On liquids, unused headspace is oxygen and light volume. A 60-count fill and a 120-count fill in the same bottle drawing are different headspace ratios; they can need different stability evaluation. Do not assume one liquid protocol covers every count.

Desiccant is not interchangeable. Clay, silica gel, and molecular sieve take up moisture at different rates and residual humidities. Name the type on the pack spec. Sublingual pieces and iron or some 5-MTHF fills more often need a named canister; cyanocobalamin in a well-sealed opaque bottle often skips desiccant until the climate file says otherwise.

When nitrogen / inert headspace. Liquids and other oxygen- or light-sensitive fills when the stability protocol requires it. Ordinary cyanocobalamin tablets in opaque HDPE with induction sealing usually do not get nitrogen as a default slogan.

Liner. Foil heat-induction liners weld a moisture/oxygen barrier and give tamper evidence. Pressure-sensitive liners are a weaker moisture file — sometimes enough for a stable cyanocobalamin tablet in a dry climate, often not enough for methylcobalamin or humid export. Skip a bottle liner only when the pack is a blister (or equivalent) that already is the barrier.

Blister. PVC/PVDC vs alu-alu is a moisture and light decision, not a decoration choice. Alu-alu is the usual talk for humid routes or methylcobalamin counts that will not live in a bottle.

Typical bottle-count conversation: 30 / 60 / 90 / 120. Supplement Facts must match the INN and mcg on the COA. Dating comes from formulation, pack, storage, and data — not a generic month range on this page.

Our OEM vitamin B12 manufacturing process runs on the finished unit.

01. RFQ — Market, BOM or card, INN, mcg, format, pack.
02. Feasibility — Premix, uniformity, stability, companions.
03. Sample / pilot — Against the approved specification, on the intended pack when overage depends on it.
04. Approval — Assay, appearance, pack.
05. Artwork — Supplement Facts versus named lines.
06. Production — Commercial batch.
07. QA release — Incoming → premix → fill/press → finished assay → pack.
08. Shipment — Export documents and dispatch.

Final MOQ depends on formula, packaging, and setup. Glance numbers above are the usual starting conversation.

Sublingual flavor systems, liquid preservative files, and dual-assay combos add time before the sample clock. Bulk kg MOQ and finished-unit MOQ are separate.